Every Form 4 that Azitra Inc (AZTR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AZTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AZTR filings page.
Azitra, Inc. President and CEO Francisco D. Salva converted preferred stock into common shares. On June 16, 2026, he converted 500 shares of Series A Convertible Non-Redeemable Preferred Stock into 4,064,050 shares of common stock for no additional consideration, as provided in the Series A Certificate of Designations and subject to Beneficial Ownership Limitations. Following the automatic conversion, his reported beneficial ownership is 4,086,291 shares of common stock, which includes 22,241 incentive stock options exercisable within 60 days of June 16, 2026.
Azitra, Inc. Chief Financial Officer Norm Staskey received a grant of 35,524 stock options to buy common shares. The options have an exercise price of $0.2127 per share and expire on April 20, 2036. After this grant, Staskey holds 35,524 options directly.
One third of the options will vest on the one-year anniversary of the grant date, and the remaining two thirds will vest in equal monthly installments over the following two years. This is a compensation-related award rather than an open-market purchase or sale.
Azitra, Inc. reported that President and CEO Francisco D. Salva received a grant of stock options covering 220,879 shares of common stock. The options have an exercise price of $0.2127 per share and expire on April 20, 2036.
According to the vesting terms, one-third of the options vest on the one-year anniversary of the grant date, and the remaining two-thirds vest in equal monthly installments over the following two years. After this grant, Salva directly holds options for 220,879 underlying shares.
Azitra, Inc. reported that Chief Operating Officer Travis Whitfill received a grant of stock options covering 64,300 shares of common stock. The options carry an exercise price of $0.2127 per share and expire on April 20, 2036.
According to the vesting terms, one-third of the options will vest on the one-year anniversary of the grant date, and the remaining two-thirds will vest in equal monthly installments over the following two years. After this grant, Whitfill holds 64,300 stock options directly.
Azitra, Inc. President and CEO Francisco D. Salva reported significant insider purchases of derivative securities. On March 18, 2026, he bought 500 shares of Series A Convertible Non-Redeemable Preferred Stock, which has a stated value of $1,000 per share and automatically converts into 8,128.1 shares of common stock per preferred share once specific stockholder approvals and a charter amendment are obtained.
He also purchased 4,064,050 Series B Warrants and 4,064,050 Series C Warrants, each exercisable for common stock at $0.123 per share. The Series B Warrants become exercisable upon stockholder approval and expire 18 months afterward, while the Series C Warrants become exercisable upon stockholder approval and terminate 30 days after Azitra publicly announces data from its planned human cosmetic study using filaggrin technology.
Azitra, Inc. reported an insider equity award for a senior executive and director. On 12/19/2025, the reporting person was granted stock options to acquire 23,724 shares of common stock at an exercise price of $0.2968 per share. These options expire on 12/19/2035.
According to the vesting terms, 25% of the common stock underlying the option vests on the grant date, with the remaining balance vesting in equal monthly installments over the following 36 months of continuous service. After this grant, the reporting person beneficially owns 23,724 derivative securities, held directly.
Azitra, Inc. reported an equity award to its President, CEO and director, Francisco D. Salva. On 12/19/2025, he received a stock option to buy 59,309 shares of Azitra common stock at an exercise price of $0.2968 per share. The option expires on 12/19/2035.
According to the vesting terms, 25% of the shares vest on the grant date, with the remaining shares vesting in equal monthly installments over the next 36 months of continuous service. Following this grant, 59,309 derivative securities are beneficially owned directly.
Azitra, Inc. director Barbara Ryan reported receiving a new stock option grant. On 12/19/2025, she was awarded options to purchase 3,003 shares of Azitra common stock at an exercise price of $0.2968 per share. These options are held directly.
According to the vesting terms, 25% of the underlying shares vest on the grant date, referred to as the Vesting Commencement Date. The remaining shares vest in equal monthly installments over the following 36 months of continuous service. The options have an expiration date of 12/19/2035.
Azitra, Inc. reported an insider equity award for its Chief Financial Officer on a Form 4. On 12/19/2025, the CFO received stock options to buy 15,015 shares of Azitra common stock at an exercise price of $0.2968 per share. These options are exercisable through 12/19/2035.
According to the vesting terms, 25% of the shares underlying the option vest on the grant date, and the remaining balance vests in equal monthly installments over the next 36 months of continuous service. Following this transaction, the reporting person beneficially owns 15,015 derivative securities directly.
Azitra, Inc. director John R. Schroer reported receiving a stock option grant. On 12/19/2025, he was granted options to purchase 3,003 shares of Azitra common stock at an exercise price of $0.2968 per share, with no purchase price for the option itself.
According to the vesting terms, 25% of the shares underlying the option vest on the grant date, designated as the vesting commencement date. The remaining shares vest in equal monthly installments over the next 36 months of continuous service. The options are scheduled to expire on 12/19/2035, and following this grant Schroer beneficially owns 3,003 derivative securities directly.